PredictCan Biotechnologies is proud to share its new publication in Scientific Reports
This study is a collaboration with the University Hospital Centre of Montpellier, of Lyon, and of Paris. We are grateful to Pr. Eric Assenat, Pr. Edouard Tuaillon, Pr. Marianne Ziol, Dr. Marie Dupuy, and Dr. Séverine Tabone-Eglinger for their precious contribution to this work. We have previously shown that our cell educating technology is a powerful system to predict and to understand the mechanism of idiosyncratic drug-induced liver injury (iDILI) at early stage of drug development. In the present work, we demonstrate the broad applicability of our cell educating technology in the context of liver cancer showing that it can mimic the tumor phenotype of each patient. Until today, microphysiological systems (MPS) for liver cancer including organoids, can only highlight patient-specific response to treatment, but they never demonstrate a correlation between in vitro prediction and clinical treatment responses. For the first time, we report that our non-invasive and animal-free technology achieved a good prediction performance , in only one week, of clinical outcomes with an accuracy of 89% of more than 30 case report studies. Our technology offers a safer way to select highly valuable new compounds to treat liver cancer and it opens a near perspective to personalized medicine.
Official collaboration between PredictCan Biotechnologies and PRADO, Preclinical Research and Development Organization to develop alternative solutions to animal testing.
Animal testing plays a critical role in gaining important knowledge needed to thoroughly evaluate the products towards reducing the health risks and sufferings to human and animals. The current regulatory framework of various countries and FDA permits, encourages, and supports the use of new alternative methods to animal testing that produce scientifically valid data and meet the regulatory requirements. PredictCan Biotechnologies and PRADO collaborate to develop models for idiosyncratic drug-induced liver injury (iDILI) as an initial step. PRADO is a Preclinical Research and Development Organization Private Limited, based in Pune India. PRADO is one of the emerging, global, independent market leaders in providing preclinical services. The company supports Pharmaceutical, Biopharma, Biotech, Medical Devices, Pesticides and Agrochemicals, Food, Vaccine, and Animal Health Industries by providing high quality preclinical services to meet their regulatory requirements. PredictCan Biotechnologies is a French biotech based in Montpellier France. PredictCan has long-lasting expertise in translational research and precision medicine to deliver innovative tools for cancer detection and treatment. The company owns a unique cell educating technology to generate animal-free and non-invasive subject-centric models for iDILI detection and drug efficacy testing. We provide cutting-edge solutions to patients, clinicians, and pharmaceutical industries supporting their combat against diseases. PredictCan Biotechnologies CEO, Hong Tuan DUONG said that we have developed a novel technology, which offers unique, individual-centric model to analyze iDILI risk. So, this model will reduce the testing time and will be economical. PRADO CEO, Dr. Pralhad Wangikar said that we are excited to use non-animal and human-relevant methods. Various models are being tested as an alternative to animal testing however, the model developed by PredictCan Biotechnologies is innovative and we look forward that this model will help in predicting the human biology more accurately and can complement, or in some cases, replace traditional animal models.
Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy.
sing individual-centric model to detect immune-mediated idiosyncratic drug-induced liver injury at preclinical stage
Using individual-centric model to detect immune-mediated idiosyncratic drug-induced liver injury at preclinical stage
sing individual-centric model to detect immune-mediated idiosyncratic drug-induced liver injury at preclinical stage
Dissecting the idiosyncratic drug-induced liver injury (iDILI)-initiating mechanism using the individual-centric model: the role of the innate immune response
PredictCan members attended the EUROTOX 2024 in Copenhagen
Our CEO Dr Hong Tuan DUONG, discussed the use of individual-centric spheroid model to decipher the initiating-mechanism of immune mediated idiosyncratic drug-induced liver injury by presenting the poster “Dissecting the idiosyncratic drug-induced liver injury (iDILI)-initiating mechanism using the individual-centric model: the role of the innate immune response” While Dr Sara CHERRADI, the CTO of the compagny showed the power of using educated spheroids to detect immune-mediated idiosyncratic drug-induced liver injury through the poster “Using individual-centric model to detect immune-mediated idiosyncratic drug-induced liver injury at preclinical stage”
Uncovering the mechanism of troglitazone-mediated idiosyncratic drug-induced liver injury with individual-centric models
PredictCan is part of the North American 3Rs collaborative as a bronze-level initiative member
We are pleased to announce that PredictCan Biotechnologies joined the North American 3Rs collaborative as a bronze-level initiative member. The 3Rs collaborative is a non-profit organization that facilitates collaborative opportunities between academics, pharmaceutical companies, contract research organizations, government organizations, and regulatory agents to refine, reduce, and replace animals in research. As an active member, PredictCan biotechnologies invests considerable efforts in developing state-of-the-art individual-centric spheroid models using our proprietary cell educating technology for meaningful 3Rs impacts. Find us on 3Rs website in the MPS Tech Hub widget at Microphysiological systems companies – 3RsC (3rc.org)